Abstract: Provided herein are methods for classifying how a subject having a cancer will respond to immunotherapeutic (IT) therapy based on the subject's immunosignature or frameshift signature. Also provided herein are methods for classifying a subject having a cancer as having a good prognosis or a poor prognosis based on the subject's immunosignature or frameshift signature.

Abstract: Tissue sample management systems include a central network, a medical professional system, and a pathology lab system for processing a tissue sample in a matrix having a sectionable code. At least the pathology lab system includes at least one imaging device, and the central network is configured to process images from the at least one imaging device to identify and record at least the sectionable code of the matrix. Methods for tissue sample processing include providing a matrix having a sectionable code and measurement marks, the matrix for receiving a tissue sample, and identifying the sectionable code from an image taken of the tissue sample in the matrix. Tissue sample-receiving matrices include a sectionable alphanumeric code or bar code, a tissue sample receptacle, and measurement marks formed along a sidewall thereof. The matrices include one or more proteins and one or more lipids.

Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.

Abstract: The present disclosure relates to methods of identifying components present in intact lipoprotein particles. Methods provided include single particle mass spectrometry, such as charge detection mass spectrometry (CDMS). Distinct subtypes and subpopulations that exist within lipoprotein density classes are determined based on simultaneously measured m/z and charge of ionized lipoprotein particles.

Abstract: Provided herein are methods implemented by a processor in a computer for designing a clamp peptide comprising the structure A1-B-A2 wherein A1 is a first peptide arm that binds to a first binding site of a target protein, A2 is a second peptide arm that binds to a second binding site of the target protein, and B is a bridge peptide which links A1 to A2. Also provided herein are computer-readable storage media having stored thereon machine-readable instructions executable by a processor and systems. Related methods of manufacturing a clamp peptide and the clamp peptides manufactures by the methods are provided.

Abstract: The present invention provides a complex of LNA probe and graphene oxide, and a nucleic acid detection method using the same. In the present invention, LNA-containing molecular beacon is conjugated through covalent bonding with graphene oxide, a single strand of the molecular beacon binds to a target nucleic acid to form a complex, and the complex is separated from graphene oxide to induce a fluorescence signal. The molecular beacon and graphene oxide can be covalently bonded to minimize non-specific signals, and a LNA-added molecular beacon is designed in a double strand to detect a very low concentration of target nucleic acid with high sensitivity, as well as a fluorescent signal, and the multiple target nucleic acids can be detected simultaneously through diversification of the fluorescent signal to enable easy and accurate detection of a nucleic acid biomarker whose specific expression level is specifically changed according to diseases and disease progression.

Abstract: A prefabricated polymeric layer to be used in a matrix-assisted laser desorption/ionization (MALDI) based system, the prefabricated polymeric layer including a first sublayer; and a second sublayer attached to the first sublayer, wherein the second sublayer includes a sample holder. At least one of the first sublayer and the second first sublayer includes a polymeric material, and the prefabricated polymeric layer is to be added to a target material to be examined by the MALDI system.

Abstract: The present disclosure relates to a method of identifying components present in a lipoprotein. Methods provided include single particle mass spectrometry, such as charge detection mass spectrometry (CDMS). Distinct subpopulations that exist within lipoprotein classes are determined by correlating m/z and mass.

Abstract: Methods of detecting a target in a sample are provided. Kits for performing the methods described herein are also provided.

Abstract: The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti-CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL).

Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

Abstract: Disclosed is a non-invasive method for assessing in a subject the presence and severity of a liver lesion, or the risk of death or liver-related events, including: 1) performing at least three binary logistic regressions on at least one variable, performed on the same variable(s) but each directed to a different single diagnostic target, thereby obtaining at least three scores; 2) combining the scores from step 1) in a multiple linear regression to obtain a new multi-targeted score; 3) optionally sorting the multi-targeted score obtained in step 2) in a classification of liver lesion stages or grades, thereby determining to which liver lesion stage or grade the subject belongs based on his/her multi-targeted score. Also disclosed is a single multi-targeted non-invasive test obtained by the combination of single-targeted non-invasive tests providing a unique score and a unique classification with improved accuracy compared to single-targeted diagnostic tests.

Abstract: The present disclosure provides a chimeric receptor binding protein (RBP) resistant to proteolytic digestion wherein said RBP comprises a portion of a receptor binding protein derived from a bacteriophage fused through a designed linker region consisting of 1 to 70 amino acids, to a portion of a receptor binding protein derived from a different bacteriophage, wherein said linker region is designed to be resistant to proteolytic digestion.

Abstract: Cancer patients make antibodies to tumor-derived proteins that are potential biomarkers for early detection. Twenty-eight antigens have been identified as potential biomarkers for the early detection of basal-like breast cancer (Tables 1, 2). Also, a 13-AAb classifier has been developed that differentiate patients with BLBC from healthy controls with 33% sensitivity at 98% specificity (Table 3).

Abstract: Described herein are digital microfluidic (DMF) devices and corresponding methods for managing reagent solution evaporation during a reaction. Reactions on the DMF devices described here are performed in an air or gas matrix. The DMF devices include a means for performing reactions at different temperatures. To address the issue of evaporation of the reaction droplet especially when the reaction is performed at higher temperatures, a means for introducing a replenishing droplet has been incorporated into the DMF device. A replenishing droplet is introduced every time when it has been determined that the reaction droplet has fallen below a threshold volume. Detection and monitoring of the reaction droplet may be through visual, optical, fluorescence, colorimetric, and/or electrical means.

Abstract: Embodiments include assay devices within a single use, disposable cassette for biochemical assays with at least one fluid well and at least one capillary valve. The capillary valve in combination with motion of porous sheets within the assay leads to addition of liquid reagents at different times to the assay although a user adds the liquid reagents to the cassette simultaneously.

Abstract: The invention generally relates to methods for distinguishing a rare genetic variation in a nucleic acid sequence.

Abstract: The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.

Abstract: Presented are systems and methods that perform noninvasive glucose monitoring using mid-infrared self-emission of the human body that acts as a background radiation emitter. Various embodiments accomplish this by taking advantage of the guided-mode resonance (GMR) effect in a number of bandpass filters that are constructed as an array of coplanar filters. The filter array acts as a spectral separator that uses a grating layer and a thin film waveguide to form reflection and transmission filters for particular wavelengths. Unlike, common multi-layer optical filter designs that utilize numerous individual optical filters, a novel GMR filter design comprises an array of filters that may be fabricated from CMOS-compatible materials using only a few thin film and grating layers to filter light. Advantageously, this reduces manufacturing cost and allows for simultaneous monitoring of a number of wavelengths of the glucose spectrum.

Abstract: The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.

Abstract: Disclosed is an antibody in which the 80th amino acid residue in a variable region based on the Kabat method and the 171th amino acid residue in a constant region based on the Kabat method are substituted with cysteine in an antibody in which the 80th amino acid residue in the variable region and the 171th amino acid residue in the constant region are not cysteine.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: The invention relates to methods of determining whether or not an individual has or is likely to develop a neurological disease and related methods and kits.

Abstract: The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.

Abstract: Methods and kits for characterizing liver damage in an individual are provided. The methods employ the use of immune analytes as biomarkers for detecting liver damage and predicting the likelihood that an individual suffering from liver damage will experience life-threatening liver failure. Concentration values for serum albumin and other identified immune analytes are obtained or determined from a blood sample taken from the individual. The obtained concentration values are then compared to corresponding concentrations from individuals having a healthy liver. By comparing the concentrations, an individual's likelihood of developing life-threatening liver failure and needing a liver transplant within a given time period (e.g., 6 months) can be identified.

Abstract: An oligopeptide microarray and methods for the synthesis thereof are presented. Further presented is a microarray on a solid support comprising at least about 10,000 oligopeptide features per cm2 and preferably at least about 50,000 oligopeptide features per cm2.

Abstract: Methods for detection of any antibody utilizing a standardized approach applicable to any antibody which provides highly specific assays specific for individual or multiple antibodies. The methods enable improved pharmacokinetic analysis during development and clinical use of antibody-based therapies as well as determination of diagnostic and/or prognostic factors.

Abstract: Provided is a method for determining one or more kinetic parameters of binding between a first binding member and a second binding member. The method includes adsorbing the first binding member to a surface at a plurality of microspots. The second binding member is then presented to the first binding member at each of the microspots, there being a plurality of combinations of first binding member surface density and second binding member concentration among the plurality of microspots. Data indicative of a binding reaction between the first of microspots are then obtained and analyzed so as to obtain one or more kinetic parameters of the binding between the first and second binding members. Also provided is a system for carrying out the method. A method for localizing a molecular species at microspots on a surface, and a probe array produced by the method are also provided.

Abstract: The present invention is directed to the design, synthesis and use of various ?-peptides exhibiting antifungal activity. The ?-peptides are relatively short in length, adopt globally amphiphilic conformations, and cause little lysis of human red blood cells at concentrations that kill Candida albicans, a common human fungal pathogen.

Abstract: A modified or isolated composition comprising a gel. The gel includes a plurality of first polymers, each of said first polymers having first functional groups comprising a first nucleic acid sequence attached as side-chains thereto. The gel includes a plurality of second polymers, each of said second polymers having second functional groups comprising a second nucleic acid sequence attached as side-chains thereto, said first and said second functional groups forming a reversible cross-link between said first and said second polymers, wherein said cross-link comprises a plurality of hydrogen bonds between complementary base portions of said first and said second nucleic acid sequences.

Abstract: The present invention provides methods and compositions for prognosing treatment outcome in DLBCL patients, diagnosing DLBCL and monitoring efficacy of DLBCL treatment.

Abstract: The invention relates to tuberculosis diagnostic methods and devices that measure particular biomarker profiles in subjects and identify a subject having tuberculosis based on such profiles.

Abstract: Methods for monitoring whether a subject will be sensitive or resistant to treatment with an anti-SMAD7 therapy are disclosed. The methods are based on the determining of the amount of CCR9+ FOXP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FOXP3+ T cells, IFN-gamma+ T cells, and/or IL17A+ T cells in a sample from the subject. Measurement of T cell populations may be determined by flow cytometry, immunohistochemistry, and/or ELISA.

Abstract: A system, a composition, a method and a kit for identifying anti-bacterial agents are provided. The invention described herein is useful in identifying inhibitors of any bacterial stress response. Moreover, the invention can be applied to any sRNA and its target, any transcription factor and its target, and any transcription factor/sRNA pair (i.e., a transcription factor that regulates a sRNA). In particular, the present invention provides a system, a composition, a method and a kit for the identification of cyclic peptides that block the ?E pathway in Escherichia coli.

Abstract: A method of diagnosing tuberculosis (TB) disease and distinguishing between active TB and latent TB infection in a subject is described herein. A sample from the subject is stimulated with at least one Mycobacterium tuberculosis (M.tb) infection phase-dependent antigen selected from Rv0081, Rv2032, Rv1737c, Rv2389c, Rv0867c, TB18.2, Rv2099c, Rv1733c, M.tb PPD, PHA and ESAT-6/CFP-10 and the presence of at least one host marker in the sample is detected, the host marker being selected from EGF, TGF-?, TNF-?, VEGF, RANTES, IL-12(p40), IL-12(p70), IL-10, IP-10, IFN-?2, fractalkine, IFN-?, IL-13, IL-1Ra, IL-3, IL-4, IL-5, MIP-1?, ENA-78, BCA-1, TARC, X6-Ckine, eotaxin, eotaxin-2, SCF, APOA-1, APOE, HPALBN, HCF, Serum amyloid protein A (SAA), C-reactive protein (CRP), serum amyloid protein P (SAP), TIMP-1, MIP-1?, IL-6, GM-CSF, IL-1?, MMP-9, MMP-2, MCP-1, TRAIL, IL-15, IL-17F, IL-22, TNF-?, MCP-2 and MCP-4. Additional host markers may also be detected in an unstimulated sample from the subject.

Abstract: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.

Abstract: Methods, compositions and arrays for non-random loading of single analyte molecules into array structures are provided. For example, methods are presented for providing a surface comprising the plurality of array regions by exposing the surface to a solution comprising polymerase enzymes where each polymerase enzyme is bound to a binding structure having several functional moieties. The functional moieties of the binding structure react with the binding elements on the array regions such that the functional moieties on the binding structure react with other available binding sites in an array region, preventing other polymerase-binding structures from loading, and resulting in a single polymerase molecule bound to each of these regions.

Abstract: The present description relates to an in vitro method for the diagnosis of endometriosis, an in vitro method for the monitoring of endometriosis and a kit for the diagnosis of endometriosis and/or for the monitoring of endometriosis in a subject.

Abstract: This invention provides methods of using circulating diseased cells in the diagnosis, prognosis, or monitoring of diseases or conditions. The invention also provides methods of using circulating diseased cells to identify markers of diseases or conditions. This invention also provides methods for assessing the risk of developing a disease or condition, prognosing said disease, monitoring said disease progression or regression, assessing the efficacy of a treatment, or identifying a compound capable of ameliorating or treating said disease or condition.

Abstract: The present invention relates to biomarkers that are specifically recognized by autoantibodies present in a biological of patients with Rheumatoid Arthritis (RA). The invention provides methods and kits using these biomarkers for the diagnosis of RA, in particular for the diagnosis of early RA.

Abstract: The present invention relates to mass spectrometry methods employing multiple reaction monitoring (MRM) in the field of cancer therapeutics, specifically prostate cancer and melanoma.

Abstract: The present invention provides methods identifying subjects having prostate cancer (PCa) by detecting in micro-particles a pair of biomarkers. The methods disclosed can be used to distinguish subjects having PCa from those having non-malignant prostate pathologies, including benign prostatic hyperplasia. Methods for monitoring prostate cancer and assessing efficacy of prostate cancer therapies are also disclosed. Kits for detecting prostate cancer using the methods disclosed are also provided.

Abstract: The present invention relates to a method for improving a repebody protein comprising repeat modules and a nucleotide library encoding a repebody protein library for improving the repebody protein. More particularly, the present invention relates to a method for improving a repebody protein using a module evolution method of sequentially mutating repeat modules constituting the repebody protein, and a nucleotide library encoding a repebody protein library used to improve the protein. According to the module evolution method of the present invention, an improved repebody protein can be screened which has a high binding affinity and accordingly increased specificity and activity, and thus it is easy to express a repebody used as an inhibitor, a therapeutic agent, and an analysis means against a target substance.

Abstract: The present invention is directed to methods, for example phage display assays, for bioengineering peptides that bind to individual distinct nucleotides. Also provided are peptides engineered by such methods. Specifically, cyclic peptides that bind individual distinct nucleotides are provided herein.

Abstract: An anti-antibody reagent for use in a competitive or sandwich simplex or multiplex assay, said reagent comprising one or more labeled anti-antibodies for the primary antibodies to be determined in the assay, the reagent further comprising a corresponding unlabeled anti-antibody in an excess or near excess concentration with respect to their binding partners.

Abstract: This invention provides high unit density arrays of microparticles and methods of assembling such arrays. The microparticles in the arrays may be functionalized with chemical or biological entities specific to a given target analyte. The high unit density arrays of this invention are formed on chips which may be combined to form multichip arrays according to the methods described herein. The chips and/or multichip arrays of this invention are useful for chemical and biological assays.

Abstract: A surface enhanced Raman spectroscopy (SERS) marker conjugate is provided. The SERS marker conjugate comprises a metallic nanoparticle and an organometallic material attached to a surface of the metallic nanoparticle. A biosensor comprising a plurality of the SERS marker conjugates and a method of forming the SERS marker conjugate is also provided.

Abstract: The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.

Abstract: Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5. Also disclosed is a kit for detecting cancer or monitoring cancer progression.